Tumour growth and metastasis are highly dependent on the formation of new blood vessels, a process termed tumour angiogenesis. As conventional treatment strategies face challenges such as tumour resistance and recurrence, interventions targeting angiogenesis have…
Lung cancer is a disease where abnormal cells grow uncontrollably in the lungs, forming tumors that can spread to other parts of the body. It is one of the most common and deadliest cancers worldwide,…
“How long can someone live with lung cancer?” The question is often the first and most daunting one that arises after a diagnosis. It carries an immense emotional weight, and the search for an answer…
What are the first signs of lung cancer? Four to five people are diagnosed with lung cancer every minute worldwide, while three to four die from the disease during the same time. Lung cancer has…
August 29, 2025 – Beijing – The National Medical Products Administration (NMPA) of China has officially announced the approval of two Category 1 innovative drugs: Boehringer Ingelheim – Zongertinib Tablets Mechanism: Irreversible HER2 Tyrosine Kinase…
Dato DXd (datopotamab deruxtecan) has received U.S. FDA approval – a breakthrough milestone announced jointly by Daiichi Sankyo and AstraZeneca on June 23, 2025. The drug is indicated for the treatment of adults with locally…
Krazati (adagrasib) is a promising targeted therapy developed to treat certain cancers with a specific genetic mutation. If you or a loved one has been prescribed this medication, you may have many questions regarding its…
Extensive-stage small-cell lung cancer (ES-SCLC) is an aggressive form of lung cancer, accounting for ~70% of SCLC cases at diagnosis. With rapid progression and high recurrence rates, ES-SCLC has historically had a poor prognosis, but recent advances in…
Introduction Anaplastic Lymphoma Kinase (ALK) is a genetic mutation that can drive the development of certain cancers—most commonly a type of non-small cell lung cancer (NSCLC). If you or a loved one has been diagnosed…
Imdelltra™ (tarlatamab-dlle) represents a significant advancement in the treatment of extensive-stage small cell lung cancer (ES-SCLC), a particularly aggressive form of lung cancer. Developed by Amgen, this novel therapy received accelerated approval from the U.S.…
Lazcluze is a cancer medicine used to treat adults with advanced non-small cell lung cancer (NSCLC) who have not been treated before. It is used in people whose cancer cells have certain mutations (changes) in…
Bizengri represents a paradigm shift in treating NRG1+ cancers, offering hope for patients with historically poor prognoses. As precision medicine advances, RNA-based testing for NRG1 fusions will be crucial to identify eligible candidates. With ongoing research, Bizengri may soon…
